RAYNER

Omeros Corporation Reports Fourth Quarter and Year-End 2023 Financial Results

Retrieved on: 
Lunedì, Aprile 1, 2024
Mental Health, Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Science, Oncology, PIN, PNH, Patient, Sale, CUD, Graft-versus-host disease, Investment, Clinical trial, Hemolysis, Calcineurin, Emory University, ASH, Risk, L-DOPA, Thumbay Hospital, Behavior informatics, Trial of the century, Myelodysplastic syndrome, Cancer, Safety, Transplant, LID, DRI, BLA, Corporation, Paroxysmal nocturnal hemoglobinuria, Tardive dyskinesia, Parkinson's disease, Publication, DSM-IV codes, Retirement, FDA, PDE7, LDH, Hematology, Mortality, Hematopoietic stem cell transplantation, Bone marrow failure, Abstract, Society, Pharmacology, Pharmaceutical industry

Net loss from continuing operations was $39.3 million for the 2023 fourth quarter compared to $51.7 million for the prior quarter.

Key Points: 
  • Net loss from continuing operations was $39.3 million for the 2023 fourth quarter compared to $51.7 million for the prior quarter.
  • Total operating expenses for the fourth quarter of 2023 were $39.8 million compared to $48.2 million for the third quarter of 2023.
  • Interest expense during the fourth quarter of 2023 was $7.1 million compared to $7.9 million during the prior quarter.
  • During the fourth quarter of 2023, we earned $3.4 million in interest and other income compared to $4.4 million in the third quarter.

OUT NOW New Book by Michael Ashcroft 'Red Queen? The Unauthorised Biography of Angela Rayner'

Retrieved on: 
Martedì, Marzo 19, 2024
Labour Party, Conservative Party, Cabinet, Ashcroft Technology Academy, Education, Gallantry, Anglia Ruskin University, Commons, Ageing, Heroes, Royal Humane Society, Political lists, Child, Politics, Imperial War Museum, House, Victoria Cross, Keir Starmer, International Strategic Studies Association, Trustee, Labour, Book

After becoming a care worker, she was a trade union representative before entering the House of Commons in 2015 as the Labour MP for Ashton-under-Lyne.

Key Points: 
  • After becoming a care worker, she was a trade union representative before entering the House of Commons in 2015 as the Labour MP for Ashton-under-Lyne.
  • She served as the shadow Secretary of State for Education for four years from 2016 and was elected deputy leader of the Labour Party in April 2020.
  • Michael Ashcroft's new book follows the journey of a politician who has quickly become an outspoken and charismatic presence in British public life.
  • Lord Ashcroft is an award-winning author who has written twenty-seven other books, largely on politics and bravery.

Omeros Corporation Announces Additional Royalty Monetization with DRI Healthcare Trust

Retrieved on: 
Giovedì, Febbraio 1, 2024
Biotechnology, Surgery, Health, Pharmaceutical, Optical, Omnibus spending bill, DRI, Cataract, CMS, Sale, Corporation, Medicare, Bookkeeping

Omeros Corporation (Nasdaq: OMER) today announced the sale to DRI Healthcare Acquisitions LP (“DRI”), a wholly owned subsidiary of DRI Healthcare Trust, of an expanded interest in certain royalty payments based on net sales of OMIDRIA in the United States.

Key Points: 
  • Omeros Corporation (Nasdaq: OMER) today announced the sale to DRI Healthcare Acquisitions LP (“DRI”), a wholly owned subsidiary of DRI Healthcare Trust, of an expanded interest in certain royalty payments based on net sales of OMIDRIA in the United States.
  • Under the terms of that asset purchase agreement, Omeros is entitled to receive royalties on net sales of OMIDRIA.
  • Today Omeros and DRI expanded their royalty purchase agreement, resulting in Omeros receiving from DRI an upfront payment of $115 million and entitling DRI to receive the remainder of Omeros’ royalties on U.S. net sales of OMIDRIA payable between January 1, 2024 and December 31, 2031.
  • “We are pleased to have partnered again with DRI, further monetizing our OMIDRIA royalty stream,” said Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros.

New Book by Michael Ashcroft 'Red Queen? The Unauthorised Biography of Angela Rayner'

Retrieved on: 
Lunedì, Gennaio 22, 2024
Labour Party, Heroes, House, Labour, Commons, International Strategic Studies Association, Anglia Ruskin University, Victoria Cross, Book, Education, Imperial War Museum, Ashcroft Technology Academy, Shadow, Politics, Conservative Party, Political lists, Royal Humane Society, Trustee, Keir Starmer, Gallantry

LONDON, Jan. 22, 2024 /PRNewswire/ -- Angela Rayner is one of the most arresting figures in British politics today. A self-declared socialist, she pursued an unorthodox route into politics, leaving school aged 16 while pregnant having gained no formal qualifications. After becoming a care worker, she was a trade union representative before entering the House of Commons in 2015 as the Labour MP for Ashton-under-Lyne. She served as the Shadow Secretary of State for Education for four years from 2016 and was elected deputy leader of the Labour Party in April 2020.

Key Points: 
  • A self-declared socialist, she pursued an unorthodox route into politics, leaving school aged 16 while pregnant having gained no formal qualifications.
  • After becoming a care worker, she was a trade union representative before entering the House of Commons in 2015 as the Labour MP for Ashton-under-Lyne.
  • Michael Ashcroft's new book follows the journey of a politician who has quickly become an outspoken and charismatic presence in British public life.
  • Lord Ashcroft is an award-winning author who has written twenty-seven other books, largely on politics and bravery.

Omeros Corporation Reports Second Quarter 2023 Financial Results

Retrieved on: 
Mercoledì, Agosto 9, 2023
Neurology, Biotechnology, Pharmaceutical, Oncology, Health, FDA, Clinical Trials, Other Health, DSM-IV codes, Survival, Tardive dyskinesia, Bangladesh Technical Education Board, Data analysis, Patent, Investment, Patient, Congress, BLA, Inflammation, Emory University, Therapy, Paroxysmal nocturnal hemoglobinuria, European Hematology Association, Research, Emory, Government, Proteinuria, Kidney International, CUD, Glomerulus, Manuscript, L-DOPA, Hematuria, Safety, Omeros, COVID-19, Inflammation Research, Immunoglobulin A, Fibrosis, PIN, Cancer, PNH, National Institute on Drug Abuse, LID, PDE7, Hemolysis, Complement, Clinical trial, Mannan-binding lectin, Sale, Trial of the century, IgA nephropathy, Corporation, NIDA, Society, C5, Pharmaceutical industry, Reinsurance, Music, Security (finance), Vaccine, Video game, Frontiers, Hematology, Immunology, Agency

“Our team continued building significant shareholder value throughout the second quarter of 2023,” said Gregory A. Demopulos, M.D., Omeros’ chairman and chief executive officer.

Key Points: 
  • “Our team continued building significant shareholder value throughout the second quarter of 2023,” said Gregory A. Demopulos, M.D., Omeros’ chairman and chief executive officer.
  • Total costs and expenses for the second quarter of 2023 were $40.9 million compared to $37.4 million for the second quarter of 2022.
  • Interest expense during the second quarter of 2023 was $7.9 million compared to $4.9 million during the prior year quarter.
  • During the second quarter of 2023, we earned $4.5 million in interest and other income compared to $0.7 million in the prior year quarter.

Omeros Corporation Reports Fourth Quarter and Year-End 2022 Financial Results

Retrieved on: 
Lunedì, Marzo 13, 2023
Oncology, Health, Surgery, Clinical Trials, Pharmaceutical, Biotechnology, Society, Paroxysmal nocturnal hemoglobinuria, Systematic review, Ophthalmology, Addiction, Omnibus spending bill, L-DOPA, PNH, LID, Hematopoietic stem cell transplantation, American Society of Hematology, Investment, Immunoglobulin A, Silicon, News, Manuscript, Cancer, Patient, IgA nephropathy, DSM-IV codes, PIN, Consolidated Appropriations Act, 2021, Government, Silicon Valley Bank, Diagnosis, PDE7, Tardive dyskinesia, Survival, FDA, CAA, Type, Omeros, Emory University, COVID-19, Corporation, BLA, Pharmaceutical industry, Video game, Cryptocurrency, Music, Nursing, Vaccine, Medical imaging, Online shopping, Hematology, Transplant

Net loss from continuing operations for the fourth quarter of 2022 was $46.0 million, or $0.73 cents per share.

Key Points: 
  • Net loss from continuing operations for the fourth quarter of 2022 was $46.0 million, or $0.73 cents per share.
  • During the fourth quarter of 2022, we earned royalties of $17.9 million on $35.8 million of Rayner sales of OMIDRIA.
  • Total costs and expenses for the fourth quarter of 2022 were $40.1 million compared to $50.8 million for the third quarter of 2022.
  • Interest expense during the fourth quarter of 2022 was $7.9 million, an increase of $3.0 million from the third quarter of 2022.

Omeros Corporation Receives $200 Million Milestone Payment from Rayner Surgical

Retrieved on: 
Lunedì, Febbraio 6, 2023
Biotechnology, COVID-19, Health, Pharmaceutical, Clinical Trials, Public expenditure, Ophthalmology, Asset purchase agreement, Agreement, Investment, CAA, Omnibus spending bill, Consolidated Appropriations Act, 2021, Growth, Milestone, Omeros, Corporation, Health insurance

Omeros Corporation (Nasdaq: OMER) today announced that Rayner Surgical, Inc. (“Rayner”) has paid the $200 million milestone payment due to Omeros under the Asset Purchase Agreement, dated December 1, 2021 (the “Agreement”), pursuant to which Omeros sold its ophthalmology product OMIDRIA® to Rayner in December of 2021.

Key Points: 
  • Omeros Corporation (Nasdaq: OMER) today announced that Rayner Surgical, Inc. (“Rayner”) has paid the $200 million milestone payment due to Omeros under the Asset Purchase Agreement, dated December 1, 2021 (the “Agreement”), pursuant to which Omeros sold its ophthalmology product OMIDRIA® to Rayner in December of 2021.
  • The Milestone Event, as defined in the Agreement, occurred in late December 2022, entitling Omeros to receive the milestone payment of $200 million within 30 days thereafter.
  • Full payment owed by Rayner – the milestone payment and accrued interest – was received on February 3, 2023.
  • The addition of the $200 million milestone payment from Rayner is expected to provide funding for Omeros’ operations across our pipeline well into at least 2025,” said Gregory A. Demopulos, M.D., Omeros’ chairman and chief executive officer.

Omeros Corporation Announces Royalty Monetization Transaction with DRI Healthcare Trust

Retrieved on: 
Lunedì, Ottobre 3, 2022
Biotechnology, Finance, Health, Professional Services, Pharmaceutical, PNH, Securities Exchange Act of 1934, Medicare, Immunoglobulin A, Medicare Part D coverage gap, SEC, Securities Act of 1933, Atypical hemolytic uremic syndrome, FDA, Corporation, Center, COVID-19, Asset purchase agreement, Medicare (United States), U.S. Securities and Exchange Commission, BLA, IgA nephropathy, Sale, DRI, Security (finance), Cancer, Calendar, Forward-looking statement, Centers for Medicare & Medicaid Services, CMS, Holding company, Health insurance, Pharmaceutical industry, Omeros, Glomerulopathy

Omeros Corporation (Nasdaq: OMER) today announced that Omeros has sold to DRI Healthcare Acquisitions LP (DRI), a wholly owned subsidiary of DRI Healthcare Trust, an interest in certain royalty payments based on net sales of OMIDRIA (the Purchased Receivables).

Key Points: 
  • Omeros Corporation (Nasdaq: OMER) today announced that Omeros has sold to DRI Healthcare Acquisitions LP (DRI), a wholly owned subsidiary of DRI Healthcare Trust, an interest in certain royalty payments based on net sales of OMIDRIA (the Purchased Receivables).
  • Omeros received gross proceeds from DRI of $125 million upon closing of the sale of the Purchased Receivables, which was completed pursuant to a Royalty Purchase Agreement between Omeros and DRI, dated September 30, 2022 (the Royalty Purchase Agreement).
  • Based on the payment schedule and associated caps, not until July 2028 will DRI have been paid an aggregate of $125 million, the amount that Omeros has received from DRI.
  • Royalty payments, as received from Rayner, will be allocated between Omeros and DRI each month based on the amount to which DRI is entitled.

Omeros Completes Sale of OMIDRIA® Franchise to Rayner Surgical

Retrieved on: 
Giovedì, Dicembre 23, 2021
Biotechnology, Pharmaceutical, Optical, Surgery, Oncology, Health, Medical Devices, Clinical Trials, Intraocular pressure, U.S. Securities and Exchange Commission, Life, Steroid, Inflammation, Patient, Sale, OVD, Cancer, Atypical hemolytic uremic syndrome, Blood pressure, Visual acuity, Securities Act of 1933, Corporation, Forward-looking statement, SEC, COVID-19, Quality of life, Securities Exchange Act of 1934, IgA nephropathy, Omeros, Immunoglobulin A, IFIS, Incidence, Security (finance), Uveitis, Lead, Phenylephrine, FDA, Telescopic sight, Pharmaceutical industry, IOL, OMIDRIA®, Omeros Corporation, Rayner Surgical Group Limited, OMIDRIA®, OMEROS CORPORATION, RAYNER SURGICAL GROUP LIMITED

Omeros Corporation (Nasdaq: OMER) today announced that it has completed the sale of OMIDRIA (phenylephrine and ketorolac intraocular solution) 1.0%/0.3% to Rayner Surgical Group Inc., an affiliate of Rayner Surgical Group Limited.

Key Points: 
  • Omeros Corporation (Nasdaq: OMER) today announced that it has completed the sale of OMIDRIA (phenylephrine and ketorolac intraocular solution) 1.0%/0.3% to Rayner Surgical Group Inc., an affiliate of Rayner Surgical Group Limited.
  • Together with substantial royalties to be paid by Rayner to Omeros on net sales of OMIDRIA, the transaction is valued in excess of $1 billion.
  • Rayner will pay Omeros royalties on both U.S. and ex-U.S. net sales of OMIDRIA.
  • Outside of the U.S., Omeros will receive a 15-percent royalty rate on OMIDRIA net sales throughout the applicable patent life on a country-by-country basis.

Omeros Announces Agreement to Sell OMIDRIA® Franchise to Rayner Surgical in a Transaction Valued in Excess of $1 Billion

Retrieved on: 
Giovedì, Dicembre 2, 2021
Biotechnology, Surgery, Health, Pharmaceutical, Optical, Patient, OVD, Blood pressure, Security (finance), Visual acuity, Ophthalmology, Sale, Securities Act of 1933, Cancer, IgA nephropathy, Forward-looking statement, Immunoglobulin A, Surgeon, Steroid, Inflammation, SEC, Hart–Scott–Rodino Antitrust Improvements Act, U.S. Securities and Exchange Commission, COVID-19, Uveitis, Securities Exchange Act of 1934, Corporation, IFIS, Incidence, EMA, FDA, Phenylephrine, Intraocular pressure, Atypical hemolytic uremic syndrome, Internet, Life, Growth, Quality of life, Pharmaceutical industry, Telescopic sight, OMIDRIA®, Omeros Corporation, Rayner Surgical Group Limited, OMIDRIA®, OMEROS CORPORATION, RAYNER SURGICAL GROUP LIMITED

Omeros Corporation (Nasdaq: OMER) today announced that it has entered into a definitive agreement for the sale of OMIDRIA to Rayner Surgical Group Limited.

Key Points: 
  • Omeros Corporation (Nasdaq: OMER) today announced that it has entered into a definitive agreement for the sale of OMIDRIA to Rayner Surgical Group Limited.
  • Together with substantial royalties to be paid by Rayner to Omeros on net sales of OMIDRIA, the transaction is valued in excess of $1 billion.
  • OMIDRIA will become a key product in Rayners ophthalmology franchise, which includes intraocular lenses, ophthalmic viscoelastic devices and dry eye treatments.
  • As part of the agreement, Rayner will acquire the OMIDRIA commercial organization, including the OMIDRIA sales force.